Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: oxycodone

FDA to Review Abuse-Deterrent Oxycodone Capsule

Michele B. Kaufman, PharmD, BCGP  |  May 18, 2018

FDA to Review Abuse-Deterrent Oxycodone Capsule In June, the FDA will discuss the New Drug Application for Remoxy ER at an Advisory Committee meeting. Remoxy ER is a 12-hour, abuse-deterrent, extended-release oxycodone in a capsule formulation.1 The capsule contains a sticky, thick, high-viscosity formulation to deter unapproved drug administration routes, including injection, smoking or snorting….

Filed under:Drug Updates Tagged with:adalimumabNSAIDsOxycodoneplaque psoriasistildrakizumab-asmn

FDA to Review Abuse Deterrent Oxycodone Capsule & More

Michele B. Kaufman, PharmD, BCGP  |  April 11, 2018

The FDA will discuss a New Drug Application for Remoxy ER during an upcoming advisory committee meeting and recently approved tildrakizumab-asmn to treat adults with plaque psoriasis…

Filed under:AnalgesicsDrug Updates Tagged with:FDARemoxy ERtildrakizumab-asmnU.S. Food and Drug Administration (FDA)

FDA to Review Immediate-Release Oxycodone; Plus NICE Recommends Secukinumab

Michele B. Kaufman, PharmD, BCGP  |  May 1, 2017

A new formulation of oxycodone in 10 and 15 mg doses is being reviewed by the FDA for treating pain…

Filed under:AnalgesicsBiologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:FDAFood and Drug AdministrationOpioidsPsoriatic Arthritissecukinumab

Oxycodone Capsules Put on Hold; Clinical Trials for Lupus Nephritis & SLE Therapies

Michele B. Kaufman, PharmD, BCGP  |  November 25, 2015

Due to a lawsuit, the FDA has issued only tentative approval for an extended-release oxycodone capsule. Obinutuzumab is in clinical trials for lupus nephritis, and subcutaneous belimumab is being tested for SLE…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:belimumabLupus nephritisobinutuzumabOxycodoneSLEsystemic lupus erythematosus (SLE)

Rituximab for RA Is Safe Long Term, Plus Oxycodone Update

Michele B. Kaufman, PharmD, BCGP  |  September 30, 2015

Rituximab was evaluated and found safe as a long-term RA therapy. Also, FDA Advisory Committees voted on oxycodone therapies at a joint meeting.

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:analgesicFDAFood and Drug AdministrationOxycodoneRheumatoid Arthritis (RA)rituximab

3 AC&R Study Summaries: MoCA Screening in SLE, Pediatric Social Disadvantages & Surgical Weight Loss Interventions

Oshrat E. Tayer-Shifman, MD; Kimberley Yuen, BSc, MD; Zahi Touma, MD, PhD, FACP, FACR; William Daniel Soulsby, MD; Aleksandra Kostic, BSE; Valia Leifer, MA; & Elena Losina, PhD, MSC  |  November 9, 2022

MoCA as a Screening Test in SLE Assessing the utility of the Montreal Cognitive Assessment (MoCA) By Oshrat E. Tayer-Shifman, MD, Kimberley Yuen, BSc, MD, & Zahi Touma, MD, PhD, FACP, FACR Why was this study done? Cognitive impairment is a common manifestation of systemic lupus erythematosus (SLE), with a prevalence of 40% based on…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Arthritis Care & ResearchDisparitiesObesityOsteoarthritisReading Rheum

Speak Out Rheum: How Did We Go So Wrong with Opioid Prescribing?

Richard Brasington Jr., MD, FACP, MACR  |  November 4, 2022

I have been listening to The Fighter Pilot Podcast because my fantasy career would have been to fly a jet fighter plane (not even remotely possible, given my constitution). I learned that when an aircraft accident occurs, a mishap board is convened, not to assign blame but to try to learn what went wrong and…

Filed under:AnalgesicsDrug UpdatesOpinionSpeak Out Rheum Tagged with:opioid crisisPain Syndrome FocusRheumSpeak Out Rheumatology

Colchicine: An Ancient Drug with Modern Uses

Ibrahem Salloum, MD, & Deepan S. Dalal, MD, MPH  |  August 11, 2021

Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:anti-inflammatoryColchicinedrug treatmentGoutinflammation

Mattew - Bilder und mehr / shutterstock.com

Yao Syndrome: A Case Report & Clinical Review

Peter Gorevic, MD, & Qingping Yao, MD, PhD  |  November 12, 2020

Case Presentation History of present illness A 66-year-old white woman presented with unexplained, recurrent episodes of high fever, abdominal pain, rash and arthralgias occurring over the previous three years. During typical episodes, the patient experienced flu-like symptoms, followed by fever, abdominal pain and non-bloody diarrhea without tenesmus. Her temperatures were 101–103ºF, with chills lasting up…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:case reportNOD2-associated auto­inflammatory diseaseYao Syndrome

High Opioid Prescription Rates Seen in Emergency Department-Treated Gout

Kurt Ullman  |  November 2, 2020

Acute gout can be very painful, causing patients to seek treatment in the emergency department. A retrospective study of pain interventions for gout in Rhode  Island found that nearly 30% of patients received prescriptions for opioid medications over 30 months. Of these prescriptions, over 80% were for patients who had never been exposed to opioids…

Filed under:AnalgesicsConditionsGout and Crystalline Arthritis Tagged with:Goutopioid crisis

  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences